A new study published in JMIR Dermatology shows that TikTok has become a major source of education and support for people ...
Bimekizumab yields clinically meaningful improvements in the severity of hidradenitis suppurativa over 48 weeks, shifting most patients to a mild disease, a pooled analysis of two trials shows.
Povorcitinib 75 mg achieved high-threshold lesion clearance by week 12, including 100% draining-tunnel reduction in 12%–57% and total abscess clearance in 22%–62% of participants. Phase 3 data show ...
NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU ...
Nurse Justus Bell found relief from a painful, often undiagnosed skin disease at a UVA Health clinic, the only one of its ...
In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% ...
These results suggest that ruxolitinib cream offers high levels of clinical efficacy, including deep and rapid responses, ...
Reimbursement authority NICE has said that Incyte's JAK inhibitor cream Opzelura (ruxolitinib) can be used to treat people ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsRoopal Thakkar - Executive VP of Research ...
Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...
From innovative medical devices to breakthrough therapies, these healthcare leaders are positioned to deliver strong returns for investors. BTIG analysts have identified their top healthcare picks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results